Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Moses Albert

Dermatology Chevy Chase, MD Medical Doctor

NPI 1740359017 CMS profile 351023

5454 Wisconsin Ave Ste 1400, Chevy Chase, MD 20815

Open in the dashboard

General payments

$2,169

81 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Moses Albert of Chevy Chase, MD is reported in the CMS Open Payments database as having received $2,169 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $165 2
2023 General $152 2
2021 General $152 2
2020 General $387 19
2019 General $1,313 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Moses Albert
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Moses Albert were reported at $165. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Moses Albert Dermatology median Middle half National median
2019 $1,313 $454 $129–$1,240 $163
2020 $387 $235 $81–$756 $114
2021 $152 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $152 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $165 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $302 20 payments
  2. Janssen Biotech, Inc. $302 8 payments
  3. Encore Dermatology Inc. $219 2 payments
  4. Botanix SB Inc $165 2 payments
  5. Sientra, Inc. $128 1 payment
  6. Dermavant Sciences, Inc. $128 1 payment
  7. Sun Pharmaceutical Industries Inc. $113 3 payments
  8. Novartis Pharmaceuticals Corporation $108 5 payments
  9. Pfizer Inc. $104 6 payments
  10. VYNE Pharmaceuticals Inc. $102 2 payments
  11. Other $500 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,012 79 payments
  2. Education $157 2 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $302 8 payments
  2. Impoyz $219 2 payments
  3. HUMIRA $214 15 payments
  4. SKYRIZI $201 11 payments
  5. SOFDRA $165 2 payments
  6. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $128 1 payment
  7. VTAMA $128 1 payment
  8. ILUMYA $113 3 payments
  9. COSENTYX $108 5 payments
  10. EUCRISA $104 6 payments
  11. Other $887 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

145

Median for Dermatology: 534

Drug cost

$4,157

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 23 $1,199
Betamethasone Dipropionate Generic 19 $775
Doxepin Hcl Generic 13 $654
Fluorouracil Generic 13 $539
Doxycycline Hyclate Generic 11 $319
Triamcinolone Acetonide Generic 26 $268
Mupirocin Generic 22 $211
Ketoconazole Generic 18 $194

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$69,147

Medicare's payments for the services billed

Medicare patients

293

Average age 78

Services billed

1,161

149 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 45%
Ischemic heart disease 25%
Osteoporosis 19%
Atrial fibrillation 17%
Cancer 17%
Diabetes 15%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record